Providers

Inconsistent use and wording of the “Not Better Explained” diagnostic criterion across major sleep disorder classifications may impact diagnostic accuracy, highlighting the need for greater standardization and clarity in clinical frameworks.

Patients who saw hair specialist dermatologists tended to be prescribed more therapies for their scarring alopecia.

EBO Editor in Chief Sucharu "Chris" Prakash, MD, addresses the role of nutrition in cancer prevention and treatment.

Todd Doyle, MD, of OneOncology, warns that commercial payers lag on updating bundled codes, which has slashed radiation oncology revenue and risks community cancer access in 2026.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

Prior authorization and PBM utilization management delay oncology and hematology novel therapies, shifting reimbursement risk to patients in Medicare Advantage.

CHECK-US data show chronic hand eczema is driven by multiple triggers and linked to moderate disease severity and significant quality-of-life burden.

Tim Church, MD, PhD, MPH, explains that access to care—not willpower—is the central barrier to GLP-1 use, and says employer coverage decisions are finally catching up.

Lalan Wilfong, MD, a medical oncologist well known for his work in practice transformation, said he looks forward to creating "something more or less from scratch."

Cardiac MRI tissue characterization can detect early, low-burden transthyretin cardiac amyloidosis and accurately distinguish it from similar conditions, a study found.

Biologic-naïve status and higher inflammation predict rapid skin clearance with psoriasis biologics, while palmoplantar disease may limit response.

New strategies and therapies are being developed to try and decrease the risk of bone disease and cardiovascular complications among people with severe kidney disease.

Family caregivers absorb enormous burden after a breast cancer diagnosis, so routine caregiver support is vital.

A phase 1 clinical trial specialist, Nancy L. Lewis, MD, MBS, FACP, most recently spent more than a decade at Novartis and was previously a faculty member at Fox Chase Cancer Center and Thomas Jefferson University Hospital.

Steven Kheloussi, PharmD, explores how smarter clinical tools, multidisciplinary teams, and better care coordination can improve outcomes for people with MS.

MASH can have a significant impact on patients’ quality of life, particularly if they have comorbidities or advanced fibrosis.

Mammography use fell significantly among younger, uninsured, and non-Hispanic White and Asian women from 2002-2022, with the 2009 USPSTF guideline change a likely driver.

Attempts to refine non–small cell lung cancer treatment selection have been limited by a lack of biomarkers, but recent research is expanding the potential landscape.

The law stems from the case of a beneficiary of the state workers health plan, repeatedly denied an alternative cancer treatment, only to be approved after he was too ill to be a candidate.

Chronic skin diseases are increasingly being understood as systemic conditions driven by the interconnected brain-gut-skin axis.

Novo Nordisk launches a Wegovy subscription program to reduce costs, expand access, and improve long-term adherence.

A machine learning model using routine clinical data more accurately predicted 5-year heart failure risk in patients with CKD than traditional tools.

Education and personal factors influence willingness more than physician recommendation alone, a new study found.

Combining traditional dermatopathology with PCR-based molecular testing improves diagnostic accuracy in differentiating eczema from psoriasis, particularly in ambiguous cases.

Fewer than half of phase 3 chronic spontaneous urticaria (CSU) trials reported baseline disease duration, a review found.